Cargando…

Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real‐world data analyses and experience of one center

BACKGROUND: Real‐world data of the CM regimen [cyclophosphamide (CTX) plus methotrexate (MTX)] in metronomic pattern for advanced breast cancer is limited to small‐sample or retrospective studies. This study was aimed to determine the effectiveness and safety of CM regimen in treating advanced breas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Qianyi, Lee, Kaping, Xu, Fei, Xia, Wen, Zheng, Qiufan, Hong, Ruoxi, Jiang, Kuikui, Zhai, Qinglian, Li, Yuan, Shi, Yanxia, Yuan, Zhongyu, Wang, Shusen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238669/ https://www.ncbi.nlm.nih.gov/pubmed/32390331 http://dx.doi.org/10.1002/cac2.12029

Ejemplares similares

Local treatment for liver oligometastases in breast cancer patients: identification of prognostic factors and exploration of appropriate treatment strategy
por: Jiang, Kuikui, et al.
Publicado: (2020)

Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in the Chinese population
por: Wang, Liye, et al.
Publicado: (2021)

Identification and characterization of critical genes associated with tamoxifen resistance in breast cancer
por: Zhang, Kai, et al.
Publicado: (2020)

Administration of Lapatinib with Food Increases Its Plasma Concentration in Chinese Patients with Metastatic Breast Cancer: A Prospective Phase II Study
por: Xu, Fei, et al.
Publicado: (2020)

CPSF4 promotes triple negative breast cancer metastasis by upregulating MDM4
por: Lee, Kaping, et al.
Publicado: (2021)

Bicalutamide plus Aromatase Inhibitor in Patients with Estrogen Receptor‐Positive/Androgen Receptor‐Positive Advanced Breast Cancer
por: Lu, Qianyi, et al.
Publicado: (2019)

Miller–Payne Grading and 70-Gene Signature Are Associated With Prognosis of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer After Neoadjuvant Chemotherapy
por: Wang, Liye, et al.
Publicado: (2021)

Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer
por: Soriano, Jorge L., et al.
Publicado: (2011)

Current Situation of Diagnosis and Treatment of HER2-Positive Metastatic Breast Cancer Patients in China: A Nationwide Cross-Sectional Survey of Doctors
por: Jiang, Kuikui, et al.
Publicado: (2023)

Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate
por: Dickinson, P D, et al.
Publicado: (2012)

Genetic analysis of oligo-recurrence breast cancer: correlation with clinical outcomes
por: Jiang, Kuikui, et al.
Publicado: (2023)

Clinical value of circulating ESR1 mutations for patients with metastatic breast cancer: a meta-analysis
por: Zhang, Kai, et al.
Publicado: (2018)

Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer
por: Orlando, Laura, et al.
Publicado: (2006)

Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2‐positive breast cancer: An open‐label, dose‐escalation, phase I study
por: Hong, Ruoxi, et al.
Publicado: (2021)

Reply: Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate
por: Khan, O A, et al.
Publicado: (2012)

Low-dose “metronomic chemotherapy” with oral cyclophosphamide and methotrexate in metastatic breast cancer: a case report of extraordinarily prolonged clinical benefit
por: Masci, G, et al.
Publicado: (2012)

Distribution Characteristics and Prognostic Value of Immune Infiltration in Oligometastatic Breast Cancer
por: Zhou, Danyang, et al.
Publicado: (2021)

Metastatic Primary Duodenal Adeno-Carcinoma Responding to Metronomic Oral Cyclophosphamide Chemotherapy
por: Bandyopadhyay, Anis, et al.
Publicado: (2014)

Metronomic chemotherapy with cyclophosphamide for the treatment of advanced hepatocellular cancer: A case report
por: Peristeri, Dimitra V., et al.
Publicado: (2021)

Phase II study of ‘high-dose’ celecoxib and metronomic ‘low-dose’ cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma
por: Abdel-Bary, N, et al.
Publicado: (2009)

Construction and validation of a macrophage polarization-related prognostic index to predict the overall survival in patients with early-stage triple-negative breast cancer
por: Luo, Hanjia, et al.
Publicado: (2023)

Metronomic chemotherapy
por: Maiti, Rituparna
Publicado: (2014)

Metronomic Chemotherapy
por: Cazzaniga, Marina Elena, et al.
Publicado: (2021)

Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer
por: Samaritani, Riccardo, et al.
Publicado: (2007)

Bevacizumab with metronomic chemotherapy of low-dose oral cyclophosphamide in recurrent cervical cancer: Four cases
por: Isono-Nakata, Rose, et al.
Publicado: (2018)

Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion
por: Muñoz, Raquel, et al.
Publicado: (2019)

Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer
por: Wysocki, Piotr J., et al.
Publicado: (2023)

The prognostic significance of skin involvement in breast cancer patients with chest wall recurrence
por: Zhou, Danyang, et al.
Publicado: (2023)

Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers
por: Allegrini, Giacomo, et al.
Publicado: (2012)

Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
por: Pujade-Lauraine, Eric
Publicado: (2013)

Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus
por: Duan, Fangfang, et al.
Publicado: (2021)

Systemic Therapy Combined with Locoregional Therapy Improved Survival in Oligometastatic Breast Cancer: A Single-Center Retrospective Cohort Study
por: Ma, Yuyu, et al.
Publicado: (2022)

Metronomic chemotherapy using oral cyclophosphamide and bevacizumab for recurrent cervical cancer: A multi-institutional retrospective study
por: Isono-Taniguchi, Roze, et al.
Publicado: (2022)

What is the appropriate genetic testing criteria for breast cancer in the Chinese population?—Analysis of genetic and clinical features from a single cancer center database
por: Ni, Mengqian, et al.
Publicado: (2023)

Metronomic Chemotherapy in Prostate Cancer
por: Wysocki, Piotr J., et al.
Publicado: (2022)

Acrolein: unwanted side product or contribution to antiangiogenic properties of metronomic cyclophosphamide therapy?
por: Günther, M, et al.
Publicado: (2008)

Metronomic cyclophosphamide with bevacizumab provides disease stabilization in patients with advanced uterine cancer
por: Alagkiozidis, Ioannis, et al.
Publicado: (2015)

Weight loss effects of methotrexate and cyclophosphamide
por: Bridges, Dave
Publicado: (2017)

Is Post-Transplant Cyclophosphamide the New Methotrexate?
por: Mussetti, Alberto, et al.
Publicado: (2021)

Head and neck cancer: metronomic chemotherapy
por: De Felice, Francesca, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_e7qakh465qsa16o3ful46pg9uh